Felipe Couñago, Medical Director at GenesisCare Spain, shared a post on LinkedIn:
“Excited to share that our editorial ‘Can We Wait a Little Longer? The Emerging Role of SABR in Deferring Systemic Therapy for Oligometastatic Renal Cell Carcinoma’ is now online!
Full-text access (free for 50 days).
This piece addresses a highly relevant clinical question:
Can SABR (SBRT) safely delay systemic therapy in oligometastatic RCC?
Key messages:
- Systemic therapies improve outcomes, but at the cost of toxicity and financial
- burden
- SABR achieves excellent local control with very low high-grade adverse events
- Enables clinically meaningful deferral of systemic therapy (~2.6 years)
- May influence disease progression patterns and treatment sequencing
- Highlights the role of advanced imaging and careful patient selection
While phase III evidence is awaited, the current data and biological rationale are compelling.
I am truly grateful to have been invited to contribute to this work. Special thanks to my friend, Shankar Siva, a true pioneer in this field, for his leadership and inspiration.”
Title: “Can We Wait a Little Longer?” The Emerging Role of SABR in Deferring Systemic Therapy for Oligometastatic Renal Cell Carcinoma
Authors: Edward Chmiel, Felipe Couñago, Shankar Siva
Other articles featuring Felipe Couñago on OncoDaily.